1. Home
  2. RTX vs SNY Comparison

RTX vs SNY Comparison

Compare RTX & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RTX Corporation

RTX

RTX Corporation

HOLD

Current Price

$186.45

Market Cap

234.3B

Sector

Industrials

ML Signal

HOLD

Logo Sanofi ADS

SNY

Sanofi ADS

HOLD

Current Price

$48.16

Market Cap

119.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RTX
SNY
Founded
1934
1994
Country
United States
France
Employees
N/A
N/A
Industry
Aerospace
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
234.3B
119.4B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
RTX
SNY
Price
$186.45
$48.16
Analyst Decision
Buy
Buy
Analyst Count
13
5
Target Price
$182.15
$61.50
AVG Volume (30 Days)
4.4M
2.4M
Earning Date
01-27-2026
01-29-2026
Dividend Yield
1.46%
3.31%
EPS Growth
38.64
105.93
EPS
4.87
8.67
Revenue
$85,988,000,000.00
$53,890,648,839.00
Revenue This Year
$8.82
$1.73
Revenue Next Year
$6.24
$6.49
P/E Ratio
$38.14
$5.58
Revenue Growth
8.79
N/A
52 Week Low
$112.27
$44.62
52 Week High
$193.79
$60.12

Technical Indicators

Market Signals
Indicator
RTX
SNY
Relative Strength Index (RSI) 59.42 45.33
Support Level $182.17 $47.17
Resistance Level $188.00 $48.74
Average True Range (ATR) 3.82 0.52
MACD 0.10 0.05
Stochastic Oscillator 43.20 52.96

Price Performance

Historical Comparison
RTX
SNY

About RTX RTX Corporation

RTX is an aerospace and defense manufacturer formed from the merger of United Technologies and Raytheon, with roughly equal exposure across three segments, mostly as a supplier to commercial aerospace and to the defense market: Collins Aerospace, a diversified aerospace supplier; Pratt & Whitney, a commercial and military aircraft engine manufacturer; and Raytheon, a defense prime contractor providing a mix of missiles, missile defense systems, sensors, hardware, and communications technology to the military.

About SNY Sanofi ADS

Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.

Share on Social Networks: